Pacira BioSciences (PCRX) Stock Price, News & Analysis

Company Overview

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control. The company has advanced clinical research in areas such as extended-release meloxicam formulations for soft tissue and orthopedic procedures, aiming to further expand its portfolio of non-opioid pain therapies. Pacira collaborates with healthcare providers and research partners to support clinical trials and to explore potential new indications for its proprietary technologies.

Founded in 2006 and headquartered in Parsippany, New Jersey, Pacira BioSciences markets its products throughout the United States and in select international territories. The company emphasizes education and training for healthcare professionals to ensure the safe and effective use of its therapies. Pacira’s operations encompass regulatory affairs, medical affairs, and commercial functions, all dedicated to advancing patient-centered approaches to pain management.

Key Stats

• Today's Range: $24.74 to $25.60
• 50-Day Range: $21.28 to $25.55
• 52-Week Range: $18.80 to $27.64
• Volume: 761,643 shs
• Average Volume: 578,908 shs
• Market Capitalization: $975.49 million
• P/E Ratio: 206.60
• Dividend Yield: N/A
• Price Target: $29.40
• Consensus Rating: Hold

Pacira BioSciences Stock Analysis - MarketRank™

Pacira BioSciences scored higher than 64% of companies evaluated by MarketBeat, and ranked 268th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Pacira BioSciences has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on no strong buy ratings, 3 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Pacira BioSciences has a consensus price target of $29.40, representing about 18.6% upside from its current price of $24.79.

Amount of Analyst Coverage

Pacira BioSciences has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 27.03%

Earnings Growth

Earnings for Pacira BioSciences are expected to grow by 27.03% in the coming year, from $1.85 to $2.35 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pacira BioSciences is 206.60, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.04.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pacira BioSciences is 206.60, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.25.

Price to Book Value per Share Ratio

Pacira BioSciences has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.50% of the float of Pacira BioSciences has been sold short.

Short Interest Ratio / Days to Cover

Pacira BioSciences has a short interest ratio ("days to cover") of 15.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Pacira BioSciences has recently decreased by 8.29%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pacira BioSciences does not currently pay a dividend.

Dividend Growth

Pacira BioSciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.28

News Sentiment

Pacira BioSciences has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 21 news articles for Pacira BioSciences this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for PCRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Pacira BioSciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Pacira BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $702,610.00 in company stock.

Percentage Held by Insiders

6.40% of the stock of Pacira BioSciences is held by insiders.

Percentage Held by Institutions

99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PCRX Stock Analysis - Frequently Asked Questions

How have PCRX shares performed this year?

Pacira BioSciences' stock was trading at $25.88 at the beginning of the year. Since then, PCRX stock has decreased by 4.2% and is now trading at $24.79.

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) released its earnings results on Thursday, April, 30th. The company reported $0.60 EPS for the quarter, missing the consensus estimate of $0.61 by $0.01. The business's revenue for the quarter was up 5.0% on a year-over-year basis.
Read the conference call transcript.

When did Pacira BioSciences IPO?

Pacira BioSciences (PCRX) raised $64 million in an initial public offering on Wednesday, February 2nd 2011. The company issued 4,250,000 shares at a price of $14.00-$16.00 per share.

Who are Pacira BioSciences' major shareholders?

Pacira BioSciences' top institutional investors include Hillsdale Investment Management Inc. (0.84%), Bank of New York Mellon Corp (0.77%), Principal Financial Group Inc. (0.72%) and Simplify Asset Management Inc. (0.15%). Insiders that own company stock include Jonathan Slonin, David M Stack, Daryl Gaugler, Frank D Lee, Shawn Cross, Kristen Williams, Roy Winston, Lauren Riker, Charles A Reinhart III, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson and Marcelo Bigal.
View institutional ownership trends.

How do I buy shares of Pacira BioSciences?

Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pacira BioSciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 4/30/2026
• Today: 5/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PCRX
• CIK: 1396814
• Web: www.pacira.com
• Phone: (813) 553-6680
• Fax: 302-655-5049
• Employees: 720
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Pacira BioSciences: $29.40
• High Price Target: $38.00
• Low Price Target: $24.00
• Potential Upside/Downside: +18.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.29
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.12
• Trailing P/E Ratio: 206.60
• Forward P/E Ratio: 13.40
• P/E Growth: N/A
• Net Income: $7.03 million
• Net Margins: 0.70%
• Pretax Margin: 1.79%
• Return on Equity: 10.24%
• Return on Assets: 5.47%

Debt

• Debt-to-Equity Ratio: 0.56
• Current Ratio: 4.73
• Quick Ratio: 3.35

Sales & Book Value

• Annual Sales: $726.41 million
• Price / Sales: 1.34
• Cash Flow: $3.87 per share
• Price / Cash Flow: 6.40
• Book Value: $16.62 per share
• Price / Book: 1.49

Miscellaneous

• Outstanding Shares: 39,350,000
• Free Float: 36,818,000
• Market Cap: $975.49 million
• Optionable: Optionable
• Beta: 0.32